相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies
Kiyohiko Hatake et al.
CANCER SCIENCE (2021)
Sex-Related Differences in Pharmacokinetics and Pharmacodynamics of Frequently Prescribed Drugs: A Review of the Literature
Andre Farkouh et al.
ADVANCES IN THERAPY (2020)
Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment
Yan Li et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
Jean-Marie Michot et al.
LANCET HAEMATOLOGY (2020)
Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects
Ken Ogasawara et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ken Ogasawara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform
Yoshito Tomimaru et al.
TRANSLATIONAL ONCOLOGY (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W. Rasco et al.
CLINICAL CANCER RESEARCH (2019)
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
Steven Lacy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma
Jun Zhou et al.
ONCOTARGET (2016)
CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma
Carolina Cubillos-Zapata et al.
ONCOIMMUNOLOGY (2016)
Exposure-response analysis to assess the concentration-QTc relationship of CC-122
Yan Li et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2016)
Population Pharmacokinetics of Pomalidomide
Yan Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Rosalba Camicia et al.
MOLECULAR CANCER (2015)
Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Tongmeng Yan et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice
G. R. Robertson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pathogenesis and treatment of renal failure in multiple myeloma
M. A. Dimopoulos et al.
LEUKEMIA (2008)
Renal failure associated with cancer and its treatment: An update
BD Humphreys et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
分享论文
